Adani Ports & SEZ delivered a robust operational update for April 2026, handling 43.1 million metric tonnes (MMT) of cargo—a 15% year-on-year increase. This growth was primarily driven by strong performance in container and dry cargo segments, both registering 17% yearly gains.
This segmental split reflects shifting logistics patterns and modal choices rather than operational weakness. The company's overall operational momentum remains strong, with FY26 revenue growing 25% year-on-year to ₹38,736 crore and EBITDA rising 20% to ₹22,851 crore. The rail dip highlights the challenge of balancing a diversified transport portfolio, but the core cargo handling business continues to fire on all cylinders, supported by digital integration initiatives like the SeaFlux platform that boosted marine fleet availability to 97%.
InterGlobe Aviation (IndiGo) faces a different set of operational headwinds. The airline announced the temporary suspension of its Manchester flights from August 31, 2026, citing an unfavorable operating environment.
Despite "very encouraging demand," the route economics became unsustainable. This is a tactical retreat, not a strategic withdrawal. IndiGo will return one leased Boeing 787-9 Dreamliner to Norse Atlantic Airways but continues to operate all other long-haul flights as planned. The move underscores the brutal reality of international aviation economics: even strong demand cannot indefinitely offset a 100%+ surge in fuel costs and significant detours that cripple aircraft utilization.
John Cockerill India turned in a standout performance, securing a major contract worth approximately ₹1,250–1,300 crore from JSW Vijayanagar Metallics for a Cold Rolled Non-Oriented (CRNO) steel project. This win is a testament to the company's technological leadership in steel processing lines and its proven execution capabilities. The contract covers the design, engineering, supply, and commissioning of two Annealing & Coating Lines and one Annealing & Pickling Line, to be executed over 36 months. This order significantly strengthens the company's order book, which stood at approximately ₹33 billion on a consolidated basis in March 2026. It reinforces John Cockerill's position as a preferred supplier for specialized metallurgical equipment and provides strong revenue visibility for the next three years, marking a successful turnaround from earlier challenges.
Canara Bank's Board has approved a comprehensive capital raising plan totaling ₹8,500 crore for FY 2026-27 through Basel III-compliant instruments: ₹4,500 crore via Additional Tier I (AT1) bonds and ₹4,000 crore via Tier II bonds. This move is designed to bolster the bank's already strong capital adequacy ratio (CRAR), which stood at a healthy 17.04% as of March 2026. The infusion will provide a substantial regulatory buffer, particularly important as the bank prepares for the implementation of the Reserve Bank of India's Expected Credit Loss (ECL) guidelines from April 2027. While the new debt will likely increase the bank's cost of funds by an estimated 20-30 basis points, the trade-off is clear: enhanced lending capacity to support credit growth targets of 18-20% and a fortified balance sheet to navigate future economic cycles. The bank's strong asset quality, with gross NPAs at just 1.84%, provides a solid foundation for this capital augmentation.
Dhanuka Agritech is taking a more direct route to returning value to shareholders. The agrochemical company's board approved a ₹70 crore share buyback at ₹1,400 per share for up to 5 lakh equity shares, representing 1.11% of the total paid-up capital.
The strategic objectives are multifaceted: distribute surplus cash, enhance return on equity by reducing the equity base, and provide an exit opportunity for shareholders, particularly small shareholders who have a reserved portion of the offer. The move comes on the heels of strong Q4 FY26 results, where net profit jumped 29% to ₹98 crore. With a debt-free balance sheet, cash and liquid investments exceeding ₹250 crore, and a current ratio of 3.08, Dhanuka has ample financial flexibility to execute this buyback without compromising its growth investments or operational stability.
Advait Energy Transitions is leveraging capital to build a different kind of asset base. Through its subsidiary, it secured a landmark Battery Energy Storage Purchase Agreement (BESPA) with Gujarat Urja Vikas Nigam Ltd (GUVNL) for a 150 MW / 300 MWh standalone BESS project. This agreement, structured on a Build-Own-Operate (BOO) basis with a 12-year concession period, provides exceptional long-term revenue visibility. The project is supported by 30% Viability Gap Funding (VGF) from the government, improving the project economics. The financing structure involves a total project cost of ₹180-200 crore, with a debt component of ₹90-100 crore. This deal is a transformative milestone, moving Advait from an infrastructure consultant to a critical energy transition partner. It provides a stable annuity revenue stream expected around ₹16 crore annually and establishes a strong reference project in the rapidly growing energy storage market, which is projected to be a ₹1.2 trillion opportunity by 2030.
Concord Biotech scored a significant regulatory victory with the US FDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This ANDA approval opens the door to the approximately US$ 30 million US market for this critical immunosuppressant used in organ transplants. The oral suspension formulation is particularly important for pediatric patients and those who cannot swallow tablets, giving Concord a niche advantage. This approval strengthens the company's position in the US transplant segment and complements its existing portfolio of capsules and tablets. Concord is already a market leader in fermentation-based immunosuppressant APIs, holding about 15% of the global Mycophenolate Mofetil API market. This vertical integration, combined with the new formulation approval, enhances its competitive positioning and provides a new revenue stream in a market growing at a CAGR of around 10% annually. Others +1
Bliss GVS Pharma also bolstered its regulatory credentials, with its Palghar facility receiving WHO GMP compliance certification. This achievement is crucial for a company that derives approximately 93% of its revenue from exports across 44+ countries. The certification, along with existing EU-GMP and USFDA approvals, strengthens its position in regulated markets and supports its international expansion strategy. The company is investing ₹30 crore to add 200 million units of semi-solid dosage capacity at the Palghar plant, expected to be operational by the end of FY26. This focus on quality and capacity expansion is aimed at capturing growth in high-value generics and differentiating through superior manufacturing standards. While the company's financial performance has been mixed, with net profit declining in recent quarters, these regulatory milestones provide a foundation for long-term growth in competitive global markets.
Vedanta Limited finds itself on the other side of the regulatory equation. The company disclosed that Enforcement Directorate (ED) officials visited its offices and those of its subsidiary, Hindustan Zinc Limited, in early June 2026.
This development elevates regulatory risk perception and introduces near-term uncertainty. While Vedanta has stated it is extending full cooperation, such investigations typically lead to increased legal and advisory costs, potential management distraction, and if violations are found, financial penalties. The key question for investors is the scope and outcome of the probe. In the meantime, the company's operational continuity appears intact, with no reported disruption to business activities. The incident adds a layer of complexity to Vedanta's narrative, which is already focused on a major demerger to unlock value, and serves as a reminder of the regulatory risks inherent in complex cross-border corporate structures.
